Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13

BACKGROUND: This study evaluated the existence of anti-drug antibodies (ADAs) before and 52 weeks after switching from intravenous infliximab (IFX) to intravenous CT-P13 in patients with rheumatoid arthritis (RA). METHODS: We performed a prospective observational study. Twenty-eight patients (7 male...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakane, Hideo, Okamura, Koichi, Inoue, Makoto, Inoue, Hiroshi, Yonemoto, Yukio, Mitomi, Hirofumi, Tsuchida, Kosei, Suto, Takahito, Kaneko, Tetsuya, Chikuda, Hirotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727853/
https://www.ncbi.nlm.nih.gov/pubmed/36474258
http://dx.doi.org/10.1186/s41927-022-00304-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727853/
https://www.ncbi.nlm.nih.gov/pubmed/36474258
http://dx.doi.org/10.1186/s41927-022-00304-9

Ejemplares similares